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 Background 
Copy number variants (CNVs) play a significant role in disease pathogenesis in a small subset of 
individuals with schizophrenia(∼2.5%). Chromosomal microarray testing is a first-tier genetic test for 
many neurodevelopmental disorders. Similar testing could be useful in schizophrenia. 
 
Aims 
To determine whether clinically identifiable phenotypic features could be used to successfully model 
schizophrenia-associated (SCZ-associated) CNV carrier status in a large schizophrenia cohort. 
 
Method 
Logistic regression and receiver operating characteristic (ROC) curves tested the accuracy of readily 
identifiable phenotypic features in modelling SCZ-associated CNV status in a discovery data-set of 
1215 individuals with psychosis. A replication analysis was undertaken in a second psychosis data-set 
(n = 479). 
 
Results 
In the discovery cohort, specific learning disorder (OR = 8.12; 95% CI 1.16–34.88, P = 0.012), 
developmental delay (OR = 5.19; 95% CI 1.58–14.76, P = 0.003) and comorbid neurodevelopmental 
disorder (OR = 5.87; 95% CI 1.28–19.69, P = 0.009) were significant independent variables in 
modelling positive carrier status for a SCZ-associated CNV, with an area under the ROC (AUROC) of 
74.2% (95% CI 61.9–86.4%). A model constructed from the discovery cohort including developmental 
delay and comorbid neurodevelopmental disorder variables resulted in an AUROC of 83% (95% CI 
52.0–100.0%) for the replication cohort. 
 
Conclusions 
These findings suggest that careful clinical history taking to document specific neurodevelopmental 
features may be informative in screening for individuals with schizophrenia who are at higher risk of 
carrying known SCZ-associated CNVs. Identification of genomic disorders in these individuals is likely 
to have clinical benefits similar to those demonstrated for other neurodevelopmental disorders. 
 
Schizophrenia is a clinically heterogeneous syndrome with substantial heritability. Common small 
genetic risk factors (polygenic risk) collectively account for some 30% of heritability.1 Copy number 
variants (CNVs) (DNA segments of >1 kilobase, present at higher (duplication) or lower (deletion) 
number than in a reference genome) have a larger role to play in a small subset of cases. There is 
evidence of genome-wide significant association for at least eight CNV loci in schizophrenia.2 
Individually these events are of moderate penetrance for schizophrenia, with reported odds ratios 
(ORs) of 2–30, which indicates that they are likely to have a substantial role in disease aetiology, at 
least for a small group of patients.3 Almost all of these CNVs are pleiotropic; for carriers of any one 
of the schizophrenia- associated (SCZ-associated) CNVs, the risk of developing any 
early developmental disorder (e.g. intellectual disability, autism spectrum disorder, developmental 
delay) is significantly higher than the risk of developing schizophrenia itself.3 Even in the absence of 
a psychiatric diagnosis, carriers of CNVs associated with schizophrenia have significant but variable 
cognitive deficits.4 These CNVs are therefore potentially pathogenic and clinically significant, but 
outcomes range from subtle cognitive effects to severe neurodevelopmental disorders. Despite 
significant progress in our understanding of the genetics of schizophrenia, the process of translating 
SCZ genetic discovery into clinical impact is in its infancy. 
Chromosomal microarray (CMA) testing is recommended as a first-tier genetic test in autism, 
developmental delay and intellectual disability.5 Because a smaller proportion of people with 
schizophrenia (∼2.5%) carry known pathogenic CNVs, routine testing is not currently recommended. 
However, a genetic diagnosis may be empowering for patients and their families, it can inform 
screening for relevant medical comorbidities and help in reproductive planning. 6 The identification 
of clinical symptoms or demographic features that differentiate people with schizophrenia who carry 
SCZ-associated CNVs may be helpful in clarifying who might benefit most from testing. On the basis 
of the known overlap with other neurodevelopmental disorders and previously reported phenotype 
studies3,7–15 we hypothesised that individuals with schizophrenia who carry SCZ-associated CNVs 
are more likely to have phenotypic features suggestive of pre-existing neurodevelopmental 
compromise, earlier onset of psychotic symptoms or a positive family history of 
neurodevelopmental disorder. The objective of this work was to determine whether clinically 




Selection of phenotypic variables 
A literature review was conducted in PubMed from January 2008 to February 2016 to identify clinical 
and phenotypic features reported to be associated with copy number variation in schizophrenia 
using the search terms ‘schizophrenia’, ‘copy number variant’ and ‘phenotype’. Publications that 
specifically described CNV-associated clinical and phenotypic features in schizophrenia were 
selected to identify neurodevelopmental phenotypic categories. Identified phenotypic domains 
included early onset of psychosis; premorbid cognitive difficulties; delays in developmental 
milestones; family history of neurodevelopmental disorder; and syndromal characteristics 
(dysmorphic features, congenital malformations). Eight specific features falling within these domains 
were identified through expert clinical consensus that are readily identifiable in a standard clinical 
evaluation and therefore ultimately of clinical utility and acceptability. Subsequently, ‘dysmorphic 
features’ and ‘congenital anomalies’ were excluded because reliable identification of these features 
requires additional training or clinical tools.16 The phenotypic variables selected for analysis are 
outlined in Table 1. 
 
Clinical sample 
The discovery data-set 
The discovery data-set consisted of 1215 individuals of Irish ancestry for whom both clinical 
phenotype and genome-wide SNP array data were available.17 The individuals were all over 18 years 
of age and had a diagnosis of schizophrenia or schizoaffective disorder after a structured clinical 
assessment (as described by First et al18). Written informed consent was obtained from all 
participants. Diagnosis was made on the basis of the consensus lifetime best estimate method using 
all available information (interview, family or staff report, chart review) with DSM-IV criteria as per 
the Structured Clinical Interview for DSM-IV-TR Axis I Disorders, research version, patient edition 
(SCID-I/P). Each referral centre obtained local research ethics committee (REC) approval. 
There was a preponderance of males in this sample (64%). 
Phenotypic data were collected retrospectively from an existing research cohort.17 The phenotypic 
data were collected from the SCID-I/P and consisted of interview self-reports. The definitions applied 
to identify a positive history of the phenotypic variables are outlined in Table 1. Phenotypic data 
were coded as categorical variables (missing information is described in supplementary Table 1, 
available at https://doi.org/10.1192/bjp.2019.262). 
 
The replication data-set 
The replication data-set was obtained from 19 879 schizophrenia cases published by the 
Schizophrenia Working Group of the Psychiatric Genomics Consortium (PGC) cohorts (representing 
40 cohorts excluding data on Irish individuals).2 Contributors of the constituent data-sets were 
approached to request access to additional phenotypic data to replicate the discovery findings. Only 
one cohort (the Cardiff data-set) was identified with the requisite phenotype data and adequate 
sample size for replication (many of the well-phenotyped cohorts were small and consequently had 
no CNV carriers). 
The Cardiff data-set (n = 479) consisted of participants from the previously reported Cardiff 
Cognition in Schizophrenia (CardiffCOGS) study.19,20 In brief, the sample was recruited with REC 
approval from community, in-patient and voluntary-sector mental health services in the UK. Written 
informed consent was obtained from all participants. Participants had a clinical diagnosis of 
schizophrenia and were interviewed using the Schedules for Clinical Assessment in Neuropsychiatry 
(SCAN) and case-note review to derive a best-estimate lifetime diagnosis according to DSM-IV 
criteria. Similar to the discovery set, there was a preponderance of males in the sample (61.2%). The 
comparable phenotype variables investigated in the Cardiff data-set were: (a) ‘history of 
developmental delay’, which was directly comparable to the Irish data-set variable and was defined 
as ‘clinically relevant delays in speech, walking, coordination or diagnosed developmental problem’ 
and (b) a positive history of epilepsy, intellectual disability and/or autism spectrum disorder, which 
was included as ‘comorbid neurodevelopmental diagnosis’. Intellectual disability referred to an 
IQ <70 and clinical specialist service involvement. The autism spectrum disorder and epilepsy 
variables were interview self-report of a clinical diagnosis. Missing information is described in 
supplementary Table 2. The other phenotypic variables selected for in the initial analysis were not 
collected in this data-set. 
 
Ethical approval 
The authors assert that all procedures contributing to this work comply with the ethical standards of 
the relevant national and institutional committees on human experimentation and with the 
Helsinki Declaration of 1975, as revised in 2008. All procedures involving human participants were 
approved by the relevant local research ethics committees in Ireland and the UK, as outlined above.  
 
CNV list 
The target CNVs used in the analysis were fifteen CNVs with the evidence of association with 
schizophrenia (supplementary Table 3) analysed by Rees et al.20 Twelve of these were also 
identified in the large PGC CNV meta-analysis21 and the other three were exon-disrupting deletions 
at the NRXN1 gene, deletion at distal 16p11.2 and duplications at the Williams–Beuren region 
identified on the basis of expert consensus or evidence published after the meta-analysis.20 
 
Genotyping and CNV calling 
The Irish sample was genotyped on the Affymetrix 6.0 array (n = 802) or the Illumina 
HumanCoreExome chip (n = 413) (full details are available in the literature17). The Cardiff sample 
was genotyped using HumanOmniExpress-12v1-1_B arrays (Illumina).22 To control for platform 
effects, raw intensity data were provided to the PGC CNV analysis group. This provided a centralised 
pipeline for systematic CNV calling including multiple CNV callers run in parallel. The final CNV set 











Univariate analyses (Fisher’s exact tests) were performed first, to assess associations between 
phenotypic predictors and SCZ-associated CNV status in the Irish cohort. Multiple logistic regression 
analysis was then carried out to examine the effects of significant phenotypic variables, identified on 
univariate analysis, in modelling SCZ-associated CNV status. The final independent variables included 
in the model were those with a significance level of 0.05 following backward elimination steps. 
Model fit was assessed using Nagelkerke pseudo R2 index. 
Receiver operating characteristic (ROC) curve analysis was used to test the validity, sensitivity and 
specificity of the logistic regression parameters for modelling SCZ-associated CNV carrier status 
in the Irish discovery data-set. 
The Cardiff replication data-set included data on two of the phenotypic variables of interest. A 
multiple logistic regression model including these two variables was trained from the Irish discovery 
data-set and then applied to the Cardiff data-set. ROC curve analysis was used to assess the accuracy 
of the neurodevelopmental variables in modelling SCZ-associated CNV carrier status in the 
replication data-set. 
The results presented are not corrected for multiple comparisons and all analyses were completed in 




From the total sample of 1215 individuals in the Irish discovery data-set, 19 (1.6%) carried one of the 
15 identified SCZ-associated CNVs.20 No individuals carried more than one SCZ-associated CNV. The 
details of the CNVs and positions are listed in supplementary Table 4. The proportions of individuals 
with a positive history of phenotypic variables and SCZ-associated pathogenic CNV status are 
available in supplementary Table 5. 
Univariate analyses identified four phenotypic variables with significant associations with SCZ-
associated CNV status: ‘history of developmental delay’, ‘comorbid neurodevelopmental disorder’, 
‘history of learning difficulties’ and ‘specific learning disorder’ (Table 1). A multiple logistic regression 
model was fitted using these four variables. The variables ‘history of learning difficulties’ 
and ‘specific learning disorder’ were correlated (phi coefficient φ = 0.22) and were likely capturing 
similar phenotypic information. Backward elimination at this point removed the variable ‘history of 
learning difficulties’ from the model. The final independent variables in the model were ‘history of 
developmental delay’, ‘comorbid neurodevelopmental disorder’ and ‘specific learning disorder’. 
These variables had odds ratios of 5.19 (95% CI 1.58–14.76, P = 0.003), 5.87 (95% CI 1.28–19.69, P = 
0.009) and 8.12 (95% CI 1.16–34.88, P = 0.012) respectively when included in the logistic 
regression model (Table 2). Nagelkerke pseudo R2 for the model was 0.196, indicating that the 
phenotypic variables accounted for 19.6% of the variance in SCZ-associated CNV status in this 
sample. The performance of the three significant independent variables in modelling SCZ-associated 
CNV carrier status was tested using ROC curve analysis. An area under the ROC (AUROC) curve of 
74.2% (95% CI 61.9–86.4%) was achieved, accounting for 58.8% (95% CI 32.9–81.6%) sensitivity and 
89.1% (95% CI 87.1–90.9%) specificity in modelling SCZ-associated CNV carrier status (Table 3). 
 
Replication data-set 
Eight individuals (1.7%) in the Cardiff replication data-set (n = 479) set carried one of the 15 
identified risk CNVs, including one 1q21.2 duplication, one NRXN1 deletion, one Williams–Beuren 
region duplication, three 15q11.2 deletions and two 22q11.2 deletions. No individual carried more 
than one of these CNVs. 
The Cardiff replication data-set included data on two of the phenotypic variables of interest: ‘history 
of developmental delay’ and ‘comorbid neurodevelopmental disorder’. The Irish discovery data-set 
was used to build a multiple logistic regression model using these two variables (supplementary 
Tables 6 and 7). Applying this model to the Cardiff study population gave an AUROC of 83% (95% CI 
52.0–100.0%) in identifying SCZassociated CNV status. The sensitivity and specificity were 75.0% 
(95% CI 19.4–99.4%) and 97.6% (95% CI 95.1–99.0%) respectively (Table 4). 
 
Discussion 
We investigated whether phenotype information generated by a standard clinical assessment could 
identify people with schizophrenia at greater risk of carrying pathogenic CNVs. In a discovery cohort 
of 1215 people with schizophrenia, having a specific learning disorder (OR = 8.12, P = 0.012), 
developmental delay (OR = 5.19, P = 0.003) or a comorbid neurodevelopmental disorder (OR = 5.87, 
P = 0.009) successfully modelled positive carrier status for a SCZ-associated CNV. Other clinical 
features, such as early onset of psychosis, low educational attainment and a family history of 
neurodevelopmental disorders, were not associated with SCZ-associated CNV carrier status in this 
cohort. The three ‘neurodevelopmental’ variables showed a relatively high specificity (89.1% (95% 
CI 87.1–90.9%)) but more modest sensitivity (58.8% (95% CI 32.9–81.6%)) in modelling carrier status 
for a SCZ-associated CNV in the Irish discovery sample. Information on ‘specific learning disorders’ 
was not available for the Cardiff replication sample. On the basis of the remaining two variables, 
‘comorbid neurodevelopmental disorder’ and ‘history of developmental delay’, we applied a model 
from the original data-set to the Cardiff sample. This too showed relatively high specificity (97.6% 
(95% CI 95.1–99.0%)) but more modest sensitivity (75.0% (95% CI 19.4–99.4%)) in modelling 
carrier status for a SCZ-associated CNV. 
 
 
Recent studies have suggested that identifying people with schizophrenia who have comorbid 
intellectual disability is likely to be helpful in identifying subsets of individuals with genomic 
disorders. 
Thygesen and colleagues reported an approximately threefold higher rate of pathogenic CNVs in 
people with psychosis and intellectual disability compared with rates in the general schizophrenia 
population.24 Lowther et al examined the genome-wide burden of pathogenic CNVs in a 
schizophrenia cohort (n = 546) and demonstrated a significantly higher burden of pathogenic CNVs 
(OR = 5.01, P = 0.0001) in people with schizophrenia and low IQ (IQ <85) compared with those with 
average IQ (IQ ≥85). On the basis of their findings, the authors concluded that individuals with 
schizophrenia and low IQ should be prioritised for clinical microarray testing in clinical and research 
contexts.25 We believe that our study provides further support for this recommendation, but that 
other developmental indices, which could be captured by a clinical neurodevelopmental history, 
should also be considered in the development of any future guidelines. 
 
Implications 
A small subset of people with schizophrenia (∼2.5%) carry CNVs that substantially increase the risk 
for schizophrenia but also for other neurodevelopmental disorders. The clinical benefits of 
identifying such people been demonstrated for other neurodevelopmental disorders.5,6 Similar 
benefits are likely to apply in schizophrenia, but as these events are rare, routine genetic testing for 
all individuals is probably not indicated. Previous studies suggest that targeting people with 
schizophrenia and comorbid intellectual disability is likely to be more fruitful in identifying such 
cases.24,25 Our findings suggest that careful clinical history taking to document developmental 
delay, reported learning disorders or a comorbid diagnosis of autism spectrum disorder or epilepsy 
may also be informative in screening for people with schizophrenia at higher risk of carrying 
known SCZ-associated CNVs. 
 
These are rare events, but very large cohorts of genotyped people with schizophrenia are available 
and it is likely that whole genome sequence analysis of >30 000 such individuals will soon be 
completed. As these data are analysed the subset of people with schizophrenia who carry rare 
mutations and CNVs of likely clinical significance will increase, as has been the case for other 
neurodevelopmental disorders. Regrettably, there is a dearth of phenotype information available 
from many of the contributory cohorts. We strongly support efforts by the PGC to collect and 
standardise such phenotype information where it is available. For future cohorts, having detailed 
phenotype information together with neurodevelopmental and medical history will likely be helpful 
in refining predictor variables that ultimately may inform guidelines for genetic testing for people 
with schizophrenia. 
 
Strengths and limitations 
The strength of our study lies in the fact that we were able to build a well-characterised phenotype 
data-set, based on extensive clinical and research data compiled from previous schizophrenia 
research studies. We were able to test multiple phenotypic features for potential in identifying 
pathogenic CNV status and identify three variables that are easily clinically identified and that show 
considerable promise in identifying a high-risk group. 
 
Recurrent SCZ-associated CNVs are rare events (∼1:150– 1:1000)3 and individual cohorts are likely 
to identify only a modest number of known CNVs, as demonstrated in our sample of 1215 people 
with schizophrenia. The study highlighted the relative limitations of phenotypic information across 
schizophrenia cohorts and suggested phenotypes derived from a standard clinical 
interview that could inform future studies. Further analysis of a wider psychosis population and 
other cross-disorder analyses are also likely to be valuable. 
Our discovery and replication cohorts used retrospective phenotypic data from which we identified 
variables that provided estimates of sensitivity and specificity for modelling SCZ-associated CNV 
carrier status. Significantly larger, well-characterised phenotypic samples (e.g. prospective cohorts) 
will be required to provide more refined estimates of sensitivity and specificity to inform genetic 
screening guidelines. It will be important to consider the patient and family perspective to inform 
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